Home
Curetis

Curetis Market Share Analysis for April 2026

Health > Biotechnology and Pharmaceuticals

Domaincuretis.com

Year Founded2007

Employees51 - 200

Annual Revenue$15M - $25M

Curetis

Curetis (including company regionals)

curetis.com

See more website traffic and engagement information

Curetis Revenue up to April 2026 is 15M - 25M

revenue generated by Curetis top domains

Curetis top domains revenue over 3 years

Revenue for Curetis top domains

curetis.com15M - 25M

See more with Sales Intelligence

Total visits to Curetis's top domains

Understand Curetis market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

curetis.com899

See more with Sales Intelligence

Avg. visit duration in Curetis's top domains

Analyze Curetis engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

curetis.com--

See more with Sales Intelligence

Avg. pageviews on Curetis's top domains

See how Curetis keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

curetis.com1.08

See more with Sales Intelligence

Curetis top competitors by domain

Top similar sites in April 2026, ranked by their affinity

triconference.comCompany NameCambridge Healthtech InstituteEmployees51 - 200HQUnited States, Massachusetts, NeedhamAnnual revenue$1M - $2MTotal visits6.8KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Curetis

These are the website technologies, by industry, used by Curetis top domains

Widget (5)

Twemoji

Content Management System (3)

WordPress

Advertising (2)

PubMatic

Marketing (2)

Google Marketing Platform

More Technologies

7

See all

News & Signals from Curetis

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCuretis Group merges with OpGen, Inc..Acumen had previously licensed the nonexclusive worldwide rights for AcuSept to Curetis, which later merged with OpGen.

NewsBioVersys AG partners with Curetis Group.BioVersys is pleased to partner with Curetis, as we rapidly develop BV100 to address the unacceptably high CRAB mortality rate due to the lack of safe and efficacious treatment options for these patients.”

NewsCuretis Group is developing Unyvero A30 RQ platform for use in low and middle income countries on Sep 27th '22.OpGen subsidiary Curetis announced on Tuesday a research and development collaboration agreement with FIND, the global alliance for diagnostics, to develop the Unyvero A30 RQ platform for use in low and middle income countries.